Canagliflozin as an initial therapy in subjects with type 2 diabetes mellitus and to assess the effects of Atherogenic lipids in its glycemic control.

Trial Profile

Canagliflozin as an initial therapy in subjects with type 2 diabetes mellitus and to assess the effects of Atherogenic lipids in its glycemic control.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Mar 2017 Primary endpoint (changes in HbA1c levels from baseline to 3 months) has been met as per results published in the Drugs in R and D
    • 21 Mar 2017 New trial record
    • 11 Mar 2017 Results published in the Drugs in R and D
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top